BiVACOR
Huntington Beach, US · Founded 2008 · Delaware corporation · 80 employees on LinkedIn · 1 known investors
BiVACOR is a clinical-stage medical device company developing a Total Artificial Heart (TAH), an electro-mechanical rotary blood pump with a single magnetically levitated rotor that replaces both ventricles for patients with end-stage biventricular heart failure. The device is undergoing an FDA-approved first-in-human Early Feasibility Study as a bridge-to-transplant solution.
Founders & leadership
BiVACOR was founded in 2008 by Daniel Timms.
DT
Daniel TimmsFounder & Chief Technical Officer
JD
James DillonExecutive
WE
William E. CohnExecutive
TV
Tom VassiliadesExecutive
WC
William CohnChief Medical Officer
Board
BC
Bihua ChenBoard director
PK
MM
Matt MackeyBoard director
RK
Raymond KelleherBoard director
RW
Raymond W. CohenBoard director
JJ
Jeannette JoughinBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$24M disclosed across 2 rounds · 2023–2024
▶$9MraisedAug 2024 · 3 investors · Other TechnologyRule 506(b)
▶$9MraisedAug 2024 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Matt MackeyDirector
- Raymond KelleherDirector
- Daniel TimmsExecutive Officer, Director
- Bihua ChenDirector
- Raymond W. CohenDirector
- Jeannette JoughinDirector
- James DillonExecutive Officer, Director
- Paul KellyDirector
- Offering amount
- $28M
- Amount sold
- $9M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedFeb 2023 · 4 investors · Other TechnologyRule 506(b)
▶$15MraisedFeb 2023 · 4 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- William E. CohnDirector
- Jeannette JoughinDirector
- Paul KellyDirector
- Raymond KelleherDirector
- Daniel TimmsExecutive Officer, Director
- Matt MackeyDirector
- Bihua ChenDirector
- Tom VassiliadesExecutive Officer, Director
- Offering amount
- $36M
- Amount sold
- $15M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapSyncardia66 shared keywordsSynCardia develops the SynCardia Total Artificial Heart (STAH), an FDA-approved device that replaces both failing ventricles to restore blood flow as a bridge to heart transplant. It serves transplant-eligible patients with end-stage biventricular heart failure and the physicians and hospitals treating them.
UPMC42 shared keywordsUPMC operates a network of hospitals and health care facilities, offering medical services and specialties such as cancer care, cardiology, neurosciences, orthopaedics, and behavioral health. It provides patient tools for finding doctors, locating facilities by region, and accessing patient portals.
Uclahealth41 shared keywordsUCLA Health is an academic health system providing primary, immediate, and specialty medical care including cancer, neuroscience, transplant, orthopedics, cardiovascular, and children's care. It operates hospitals and clinics and trains medical students, with a network of locations in the Los Angeles area.
Rf Surgical37 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Companies competing with BiVACOR for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does BiVACOR do?
- BiVACOR is a clinical-stage medical device company developing a Total Artificial Heart (TAH), an electro-mechanical rotary blood pump with a single magnetically levitated rotor that replaces both ventricles for patients with end-stage biventricular heart failure. The device is undergoing an FDA-approved first-in-human Early Feasibility Study as a bridge-to-transplant solution.
- Who founded BiVACOR?
- BiVACOR was founded by Daniel Timms in 2008.
- Who are BiVACOR's investors?
- BiVACOR's investors include OneVentures.
- How much funding has BiVACOR raised?
- BiVACOR has disclosed $24M raised across 2 rounds.
- Where is BiVACOR headquartered?
- BiVACOR is headquartered in Huntington Beach, US.